FOR THE LATEST CORONAVIRUS UPDATE VISIT WWW.SACORONAVIRUS.CO.ZA

References

History References:

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

Bleimann, H ., R . Hartmann "Therapy of Gastrointestinal Functional Disorders with Iberogast® ." Der Kassenarzt, 1983; 23:52-59 .

Ohms, P . "Tablets Every Day: How Long can the Stomach Tolerate it? " Ärztl. Praxis, 1983 . 35: 3109-3110.

Steimer, P . "Iberogast® Therapy in Gastroenterology - Therapeutic Experience Report ." Der Krankenhausarzt, 1983. Vol. 12: 1005-1008 .

Bremer, W ., F . Fischer and K . Nicolay "Gastrointestinal Illnesses - Therapy with Iberogast® " Z. Allg. Med., 1983 . 59: 1706-1709 .

Brückel, M . H ., W . Gisevius "Iberis Amara Helps in Cases of Functional Stomach Complaints ." Ärztl. Praxis, 1984 . 36: 494 .

Hölscher, H. J. "Therapy of Non-specific Gastrointestinal Complaints in Elderly Patients" Therapiwoche, 1984 . 34: 657-659 .

Illing, G ., G . Sajthy "On the Antiemetic Effect of Iberogast® " Der Kassenarzt, 1984 . 24: 46-49 .

Sporrer, M . "Rapidly Effective Phytotherapy in Gastrointestinal Complaints " Medica - Seminarzeitschrift für die ärztliche Praxis, 1984 . 5

Nicolay, K . "Metoclopramide versus the Herbal Medicine Iberogast® in the Treatment of Functional Gastroenteropathies" Gastro-Entero-Hepatologie, 1984. 2:1-12.

Kohlhoff, E ., U . Hübner-Steiner "Controlled Double-blind Study of Iberogast® versus Placebo in the Treatment of Gastrointestinal Ailments due to Stress at the Workplace", Internal Study report: 8: Research Report No. 06/85 1-55 .

MacLean, N., U . Hübner-Steiner "Controlled Double-Blind Study of Iberogast® verus Placebo for the Treatment of Gastrointestinal Complaints due to Drug Intolerance", Internal Study Report 7: Research Report No. 07/85 1-61 .

MacLean, N., U. Hübner-Steiner "Controlled Double-Blind Study of Iberogast® versus Placebo for the Treatment of Gastrointestinal Complaints due to Drug Intolerance", Internal Study Report 6: Research Report No. 06/86 1-49 .

Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006 . 13 (Suppl 5): 67–74 .

Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .

Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .

Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .

Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .

Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .

Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .

Reichling, J . and R . Saller “Iberis amara L . (Bittere Schleifenblume) – Profil einer Heilpflanze .” Forsch Komplementärmed Klass Naturheilkd, 2002 . 9: 21–33 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Iberis, Hager ROM 2003, Springer Verlag, Heidelberg 2003, HN: 2001400.

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086 .

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

How to take Iberogast® References:

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19.

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

 

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

Making Iberogast® References:

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

European Medicines Agency: EMEA/HMPC/246816/2005 – “Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin .” Published 20 February 2006 . Available from: https://www .ema .europa .eu/documents/scientific-guideline/guideline-good-agriculturalcollection-practice-gacp-starting-materials-herbal-origin_en .pdf .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

European Medicines Agency: EMEA/HMPC/246816/2005 – “Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin .” Published 20 February 2006 . Available from: https://www .ema .europa .eu/documents/scientific-guideline/guideline-good-agriculturalcollection-practice-gacp-starting-materials-herbal-origin_en .pdf .

Okpanyi, S . N . “Acute oral toxicity of Iberogast® (STW 5) in the rat .” 1986 . STW FB 17/86 .

Okpanyi, S . N . “Acute oral toxicity of Iberogast® in the mouse .” 1986 . STW FB 18/86 .

van Rozendaal, A . W . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): Acute oral toxicity study in male and female Wistar rats .” 2003, Notox project no . 320265 .

van Rozendaal, A . W . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): 3-Month oral gavage toxicity study in male and female Beagle dogs followed by a 1-month recovery period .” 2003, Notox project no . 330222 .

Schoenmakers A . C . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): Combined 3 and 6-month oral gavage toxicity study in male and female Wistar rats followed by a one-month recovery period .” 2003 . Notox project no . 330211 .

Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “Micronucleus assay in bone marrow cells of the mouse with STW 5 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/Germany . Test Report 1996 . CCR project no: 538204 .

Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “In vivo/in vitro unscheduled DNA synthesis in rat hepatocytes with STW 5 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/ Germany, Test Report 1996 . CCR project no: 538203 .

Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “Micronucleus assay in bone marrow cells of the mouse with STW 5 . Test report, Proj . No . 538 204 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/Germany, Test Report 1996 . CCR project no: 538104 .

Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “In vivo/in vitro unscheduled DNA synthesis in rat hepatocytes with STW 6 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/ Germany, Test Report 1996 . CCR project no . 538103 .

Burns, L . M . “Oral (gavage) maximum tolerated dose (MTD) study in the rabbit .” 2003 . Sequani Study no: VEB0002 .

Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rabbit .” 2003 . Sequani Study no: VEB0003 .

Burns, L . M . “Oral (gavage) developmental toxicity study in the rabbit .” 2003 . Sequani Study no: VEB0004 .

Burns, L . M . “Oral (gavage) fertility and general reproductive performance dose ranging study in the rat .” 2003 . Sequani Study no: VEB0005 [Module 4 .2 .3 .5 .1 .1] .

Burns, L . M . “Oral (gavage) developmental toxicity study in the rat .” 2003 . Sequani Study no: VEB0008 [Module 4 .2 .3 .5 .1 .2] .

Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rat .” 2003 . Sequani Study no: VEB0006 [Module 4 .2 .3 .5 .1 .3] .

Burns, L . M . “Oral (gavage) fertility and early embryonic development study in the rat .” 2003 . Sequani Study no: VEB0007 [Module 4 .2 .3 .5 .1 .4] .

Burns, L . M . “Oral (gavage) pre- and post-natal developmental toxicity study in the rat .” 2003 . Study no: VEB0009 [Module 4 .2 .3 .5 .3 .1] .

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Malfertheiner, P . "STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086 .

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

What Experts say References:

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19.

Stanghellini, V ., F . K . Chan, W . L . Hasler, J . R . Malagelada, H . Suzuki, J . Tack and N . J . Talley “Gastroduodenal Disorders .” Gastroenterology, 2016 . 150(6): 1380–1392 .

Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .

Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .

Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55.

Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .

Simmen, U ., O . Kelber, R . Jaeggi, B . Büter, S . N . Okpanyi and D . Weiser . “Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor .” Naunyn Schmiedeberg´s Arch Pharmacol, 2003 . 367, (Suppl 1): R22 .

Müller, M . H ., C . Y . Liu, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine .” Phytomedicine, 2006 . 13 (Suppl 5): 100–106.

Hagelauer, D ., O . Kelber, D . Weiser, S . Laufer and H . Heinle “Effects of Substance P and Neurotensin on the contractility of ileum of mice in vitro: Inhibition by plant extract STW 5 (Iberogast®) .” Planta Med, 2007 . 73(09): P_478 .

Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis .” Mol Med, 2015 . 21(1): 1011–1024 .

Bonaterra, G . A ., O . Kelber, D . Weiser and R . Kinscherf “Mechanisms of the antiproliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro .” Phytomedicine, 2013 . 20(8–9): 691–698 .

Michael, S ., O . Kelber, S . Hauschildt, K . Spanel-Borowski and K . Nieber “Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6 .” Phytomedicine, 2009 . 16(2-3): 161–171 .

Michael, S ., H . Abdel-Aziz, D . Weiser, C . E . Muller, O . Kelber and K . Nieber “Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®(R)) in rat small intestinal preparations .” Naunyn Schmiedebergs Arch Pharmacol, 2012 . 385(4): 411–421 .

Schempp, H ., D . Weiser, O . Kelber and O . Elstner "Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast®) and its components ," Phytomedicine, 2006 . 13 Suppl 5:36-44 .

Schneider, M ., T . Efferth and H . Abdel-Aziz “Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells .” Front Pharmacol, 2016 . 7: 393 .

Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .

Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .

Wadie, W ., H . Abdel-Aziz, H . F . Zaki, O . Kelber, D . Weiser and M . T . Khayyal “STW 5 is effective in dextran sulfate sodium-induced colitis in rats .” Int J Colorectal Dis, 2012 . 27(11): 1445–1453 .

Marx, L ., D . Grundmann, S . Dominik, M . Klotz, D . Simon, H . Rabe, H . Abdel-Aziz, O . Kelber and K .-H . Schäfer “Influences of STW 5, a multi-component herbal preparation, on motility and inflammation challenges in gut and enteric nervous system (ENS) .” Digestive Disease Week 2016 . San Diego Convention Center, 2016 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

What’s in Iberogast® References:

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19.

Enck, P ., Q . Aziz, G . Barbara, A . D . Farmer, S . Fukudo, E . A . Mayer, B . Niesler, E . M . Quigley, M . Rajilic-Stojanovic, M . Schemann, J . Schwille-Kiuntke, M . Simren, S . Zipfel and R . C . Spiller “Irritable bowel syndrome .” Nat Rev Dis Primers, 2016 . 2: 16014 .

Enck, P ., F . Azpiroz, G . Boeckxstaens, S . Elsenbruch, C . Feinle-Bisset, G . Holtmann, J . M . Lackner, J . Ronkainen, M . Schemann, A . Stengel, J . Tack, S . Zipfel and N . J . Talley “Functional dyspepsia .” Nat Rev Dis Primers, 2017 . 3: 17081 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .

Reichling, J . and R . Saller “Iberis amara L . (Bittere Schleifenblume) – Profil einer Heilpflanze .” Forsch Komplementärmed Klass Naturheilkd, 2002 . 9: 21–33 .

Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .

Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .

Iberis, Hager ROM 2003, Springer Verlag, Heidelberg 2003, HN: 2001400.

Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .

Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .

Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006 . 13 (Suppl 5): 67–74 .

Angelicae radix, ESCOP monographs 2009.

European Medicines Agency: EMA/HMPC/614586/2012 – “Assessment report on Angelica sinensis (Oliv .) Diels, radix .” Published 9 July 2013 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-angelica-sinensis-oliv-diels-radix-first-version_en .pdf .

Carvi fructus, ESCOP monographs 2003.

European Medicines Agency: EMA/HMPC/715092/2013 – “European Union herbal monograph on Carum carvi L ., fructus .” Published 14 November 2014 . Available from: https://www .ema . europa .eu/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-lfructus_en .pdf .

European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https:// www .ema .europa .eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en .pdf .

Matricariae flos, ESCOP monographs 2003.

Flos Chamomillae, WHO monograph 2010.

European Medicines Agency: EMA/HMPC/294188/2013 – “Assessment report on Silybum marianum (L .) Gaertn ., fructus .” Published 5 June 2018 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-silybum-marianum-l-gaertn-fructus_en .pdf .

Silybi mariani fructus, ESCOP monographs 2009.

Fructus Silybi Mariae, WHO monograph 2002.

European Medicines Agency: EMA/HMPC/196746/2012 – “Assessment report on Melissa officinalis L ., folium .” Published 14 May 2013 . Available from: https://www .ema .europa .eu/documents/ herbal-report/final-assessment-report-melissa-officinalis-l-folium_en .pdf .

Melissae folium, ESCOP monographs 2013.

Folium Melissae, WHO monograph 2010.

Sibaev, A ., H . Abdel-Aziz, O . Kelber, H . D . Allescher and M . Storr “Mechanism of action of STW 5 and its components on motility and intestinal neurotransmission in “in vitro” model of the human colon .” Neurogastroenterol Motil, 2015 . 27 (Suppl . 2): 101 .

European Medicines Agency: EMA/HMPC/369801/2009 – “Assessment report on Chelidonium majus L ., herba .” Published 13 September 2011 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-chelidonium-majus-l-herba_en .pdf .

Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55.

Allam, S ., D . Krueger, I . E . Demir, G . Ceyhan, F . Zeller and M . Schemann “Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine .” Phytomedicine, 2015 . 22(12): 1063–1070 .

Menthae piperitae folium, ESCOP monographs 2019.

Folium Menthae Piperitae, WHO monograph 2002.

European Medicines Agency: EMA/HMPC/571122/2010 Corr . – “Assessment report on Glycyrrhiza glabra L . and/or Glycyrrhiza inflata Bat . and/or Glycyrrhiza uralensis Fisch ., radix .” Published 12 March 2013 . Available from: https://www .ema .europa .eu/documents/herbal-report/final-assessmentreport-glycyrrhiza-glabra-l/glycyrrhiza-inflata-bat/glycyrrhiza-uralensis-fisch-radix_en .pdf .

Liquiritiae radix, ESCOP monographs 2003.

Radix Glycyrrhizae, WHO monograph 2010.

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

European Medicines Agency: EMEA/HMPC/246816/2005 – “Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin .” Published 20 February 2006 . Available from: https://www .ema .europa .eu/documents/scientific-guideline/guideline-good-agriculturalcollection-practice-gacp-starting-materials-herbal-origin_en .pdf .

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Digestive Symptoms Articles References:

Enck, P ., Q . Aziz, G . Barbara, A . D . Farmer, S . Fukudo, E . A . Mayer, B . Niesler, E . M . Quigley, M . Rajilic-Stojanovic, M . Schemann, J . Schwille-Kiuntke, M . Simren, S . Zipfel and R . C . Spiller “Irritable bowel syndrome .” Nat Rev Dis Primers, 2016 . 2: 16014 .

Lacy, B . E ., F . Mearin, L . Chang, W . D . Chey, A . J . Lembo, M . Simren and R . Spiller “Bowel Disorders .” Gastroenterology, 2016 . 150(6): 1393–1407 .e1395 .

Lovell, R . M . and A . C . Ford “Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis .” Clin Gastroenterol Hepatol, 2012 . 10(7):712–721 .e4 .

Saito, Y . A ., G . M . Petersen, J . J . Larson, E . J . Atkinson, B . L . Fridley, M . de Andrade, G . R . Locke 3rd, J . M . Zimmerman, A . E . Almazar-Elder and N . J . Talley "Familial aggregation of irritable bowel syndrome: a family case-control study ." Am J Gastroenterol, 2010 . 195(4): 833-41 .

Enck, P ., F . Azpiroz, G . Boeckxstaens, S . Elsenbruch, C . Feinle-Bisset, G . Holtmann, J . M . Lackner, J . Ronkainen, M . Schemann, A . Stengel, J . Tack, S . Zipfel and N . J . Talley “Functional dyspepsia .” Nat Rev Dis Primers, 2017 . 3: 17081 .

Holtmann, G ., A . Shah and M . Morrison “Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview .” Dig Dis, 2017 . 35 (Suppl 1): 5–13 .

Drossman, D . A . and W . L . Hasler “Rome IV-Functional GI Disorders: Disorders of GutBrain Interaction .” Gastroenterology, 2016 . 150(6): 1257–1261 .

Camilleri, M ., B . Coulie and J . F . Tack “Visceral hypersensitivity: facts, speculations, and challenges .” Gut, 2001 . 48(1): 125–131 .

Mayer, E . A ., S . Bradesi, L . Chang, B . M . R . Spiegel. J . A . Bueller and B . D . Naliboff "Functional GI disorders: from animal models to drug development ." Gut, 2008 . 57(3): 384-404 .

Ford, A . C ., P . Moayyedi, B . E . Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel, E . M . M . Quigley "American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation ." Am J Gastroenterol. 2014 . 109 Suppl 1: s2-26; quiz S27 .

Hayes, P . A ., M . H . Fraher and E . M . M . Quigley "Irritable bowel syndrome: the role of food in pathogenesis and management ." Gastroenterol Hepatol (N Y), 2014 . 10(3): 164-74 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Zhou, C ., E . Zhao, Y . Li, Y . Jia and F . Li "Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials ." Neurogastroenterol Motil, 2019 . 31(2):e13461 .

De Giorgio, R ., U . Volta and P . R . Gibson "Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?" Gut, 2016 . 65(1): 169-78 .

Vazquez-Roque, M . I ., M . Camilleri, T . Smyrk, J . A . Murray, E . Marietta, J . O'Neill, P . Carlson, J . Lamsam, D . Janzow, D . Eckert, D . Burton and A . R . Zinsmeister "A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function ." Gastroenterology, 2013 . 144(5): 903-911 e3 .

Moayyedi, P ., E . M . M . Quigley, B . E. Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel and A . C . Ford "The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis ." Am J Gastroenterol, 2014 . 109(9): 1367-74 .

Halmos, E . P ., V . A . Power, S . J . Shepherd, P . R . Gibson and J . G . Muir "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome ." Gastroenterology, 2014 . 146(1): 67-75 e5 .

Halmos, E . P ., C . T . Christophersen, A . R . Bird, S . J . Shepherd, P . R . Gibson and J . G . Muir "Diets that differ in their FODMAP content alter the colonic luminal microenvironment ." Gut, 2015 . 64(1): 93-100 .

Catassi, G ., E . Lionetti, S . Gatti and C . Catassi "The Low FODMAP Diet: Many Question Marks for a Catchy Acronym ." Nutrients, 2017 . 9(3): 292 .

Drossman, D . A ., L . Chang, S . Schneck, C . Blackman, W . F . Norton and N . J . Norton "A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity ." Dig Dis SCi, 2009 . 54(7): 1532-41 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

Stanghellini, V ., F . K . Chan, W . L . Hasler, J . R . Malagelada, H . Suzuki, J . Tack and N . J . Talley “Gastroduodenal Disorders .” Gastroenterology, 2016 . 150(6): 1380–1392 .

Rasmussen, S ., T . H . Jensen, S . L . Henriksen, P . F . Haastrup, P . V . Larsen, J . Sondergaard and D . E . Jarbol “Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population .” Scand J Gastroenterol, 2015 . 50(2): 162–169 .

Marzio, L ., M . Falcucci, L . Grossi, F . A . Ciccaglione, M . G . Malatesta, A . Castellano and E . Ballone “Proximal and distal gastric distension in normal subjects and H . pylori-positive and -negative dyspeptic patients and correlation with symptoms .” Dig Dis Sci, 1998 . 43(12): 2757–2763 .

Bytzer, P . and N . J . Talley “Dyspepsia .” Ann Intern Med, 2001 . 134(9 Pt 2): 815–822 .

Tack, J ., P . Caenepeel, B . Fischler, H . Piessevaux and J . Janssens “Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia .” Gastroenterology, 2001 . 121(3): 526–535 .

Gschossmann, J . M ., G . Holtmann and E . A . Mayer “[Epidemiology and clinical phenomenology of visceral pain] .” Schmerz, 2002 . 16(6): 447–451 .

Tack, J ., I . Demedts, G . Dehondt, P . Caenepeel, B . Fischler, M . Zandecki and J . Janssens “Clinical and pathophysiological characteristics of acute-onset functional dyspepsia .” Gastroenterology, 2002 . 122(7): 1738–1747 .

Thumshirn, M . “Pathophysiology of functional dyspepsia .” Gut, 2002 . 51 (Suppl 1): i63-66 .

Wingate, D ., M . Hongo, J . Kellow, G . Lindberg and A . Smout “Disorders of gastrointestinal motility: towards a new classification .” J Gastroenterol Hepatol, 2002 . 17 (Suppl): S1-14 .

Stanghellini, V ., F . De Ponti, R . De Giorgio, G . Barbara, C . Tosetti and R . Corinaldesi “New developments in the treatment of functional dyspepsia .” Drugs, 2003 . 63(9): 869–892 .

Tack, J ., H . Piessevaux, B . Coulie, P . Caenepeel and J . Janssens “Role of impaired gastric accommodation to a meal in functional dyspepsia .” Gastroenterology, 1998 . 115(6): 1346–1352 .

Iovino, P ., C . Bucci, F . Tremolaterra, A . Santonicola and G . Chiarioni “Bloating and functional gastro-intestinal disorders: where are we and where are we going?” World J Gastroenterol, 2014 . 20(39): 14407–14419 .

Filipović, B . F ., T . Randjelovic, N . Kovacevic, N . Milinić, O . Markovic, M . Gajić, B . R . Filipović "Laboratory parameters and nutritional status in patients with functional dyspepsia ." Eur J Intern Med, 2011 . 22(3): 300-4 .

Mullan, A ., P . Kavanagh, P . O'Mahony, T . Joy, F . Gleeson and M . J . Gibney "Food and nutrient intakes and eating patterns in functional and organic dyspepsia ." Eur J Clin Nutr, 1994 . 48(2): 97-105 .

Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients ." Dig Dis Sci, 2010 . 55(1): 60-5 .

Göktaş, Z ., S . Köklü, D . Dikmen, Ö . Öztürk, B . Yılmaz, M . Asıl, H . Korkmaz, Y . Tuna, M . Kekilli, E . K . Aksoy, H . Köklü, A . Demir, G . Köklü and S . Arslan " Nutritional habits in functional dyspepsia and its subgroups: a comparative study ." Scand J Gastroenterol, 2016 . 51(8): 903-7 .

Pilichiewicz, A . N ., M . Horowitz, G . J . Holtmann, N . J . Talley and C . Feinle-Bisset "Relationship between symptoms and dietary patterns in patients with functional dyspepsia ." Clin Gastroenterol Hepatol, 2009 . 7(3): 317-22 .

Talley, N . J . and A . C . Ford "Functional Dyspepsia ." N Engl J Med, 2015 . 373(19): 1853-63 .

Van Oudenhove, L . and Q . Aziz "The role of psychosocial factors and psychiatric disorders in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 158-67 .

Brun, R . and B . Kuo “Functional dyspepsia .” Therap Adv Gastroenterol, 2010 . 3(3):145–164 .

Lovell, R . M . and A . C . Ford “Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis .” Clin Gastroenterol Hepatol, 2012 . 10(7):712–721 .e4 .

Talley, N . J ., M . M . Walker and G . Holtmann “Functional dyspepsia .” Curr Opin Gastroenterol, 2016 . 32(6): 467–473 .

Fond. G ., A . Loundou, N . Hamdani, W . Boukouaci, A . Dargel, J . Oliveira, M . Roger, R . Tamouza, M . Leboyer and L . Boyer "Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis ." Eur Arch Pyschiatry Clin Neurosci, 2014 . 264(8): 651-60 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Müller, M . H ., C . Y . Liu, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine .” Phytomedicine, 2006 . 13 (Suppl 5): 100–106 .

Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .

Wadie, W ., H . Abdel-Aziz, H . F . Zaki, O . Kelber, D . Weiser and M . T . Khayyal “STW 5 is effective in dextran sulfate sodium-induced colitis in rats .” Int J Colorectal Dis, 2012 . 27(11): 1445–1453 .

Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .

Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .

Khayyal, M . T ., M . Abdel-Tawab, S . El-Sayed, B . Vinson and A . Abdel-Aziz "Effect of the herbal preparation, STW 5, on the microbiome in an experimental model of functional dyspepsia " Gastroenterology, 2017 . 152 (5): S1009 .

El-Ghazaly, M . A ., R . M . El-Hazek and M . T . Khayyal "Protective effect of the herbal preparation, STW 5, against intestinal damage induced by gamma radiation in rats" Int J Radiat Biol, 2015 . 91 (2): 150-6 .

Deding, U ., C . Torp-Pedersen and H . Bøggild "Perceived stress as a risk factor for dyspepsia: a register-based cohort study ." Eur Gastroenterol Hepatol, 2017 . 29(5): 560-567 .

Hassanzadeh, S ., P . Saneei, A . H . Keshteli, H . Daghaghzadeh, A . Esmaillzadeh and P . Adibi "Meal frequency in relation to prevalence of functional dyspepsia among Iranian adults ." Nutrition, 2016 . 32(2): 242-8 .

Wang, Y . P ., C . C . Herndon and C . L . Lu "Non-pharmacological Approach in the Management of Functional Dyspepsia ." J Neurogastroenterol Motil, 2020 . 26(1): 6-15 .

Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016 . 96: 2275-283 .

Boeckxstaens, G ., M . Camilleri, D . Sifrim, L . A . Houghton, S . Elsenbruch, G . Lindberg, F . Azpiroz and H . P . Parkman "Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation ." Gastroenterology, 2016 . 150: 1292-1304 .

Wallace, J . L . "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiol Rev, 2008 . 88(4): 1547-65 .

Annibale. B ., G . Esposito and E . Lahner " A current clinical overview of atrophic gastritis ." Expert Rev Gastroenterol Hepatol, 2020 . 14(2): 93-102 .

Rajindrajith, S ., J . Zeevenhooven, N . M . Devanarayana, B . J . C . Perera and M . A . Benninga "Functional abdominal pain disorders in children ." Expert Rev Gastroenterol Hepatol, 2018 . 12(4): 369-390 .

Berg, L . K ., E . Fagerli, M . Martinussen, A . O . Myhre, J . Florholmen and R . Goll "Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test ." Scand J Gastroenterol, 2013 . 48(8): 936-43 .

European Medicines Agency: EMEA/HMPC/193910/2007 – “Assessment report on Mentha X piperita L ., folium .” Published 4 September 2008 . Available from: https://www.ema.europa.eu/documents/ herbal-report/assessment-report-mentha-x-piperita-l-folium_en.pdf .

European Medicines Agency:  EMEA/HMPC/263293/2006 - "Assessment repot on Foeniculum vulgare Miller subsp. vulgare Var. dulce (miller) Thellung, fructus ." Published 16 February 2010 . Available from: https://www.ema.europa.eu/en/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc_en.pdf .

Anisi Fructus, ESCOP monographs 2014 .

European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https://www.ema.europa.eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en.pdf .

Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55 .

Müller, M . H ., C . Y . Liu, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine .” Phytomedicine, 2006 . 13 (Suppl 5): 100–106 .

Simmen, U ., O . Kelber, R . Jaeggi, B . Büter, S . N . Okpanyi and D . Weiser . “Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor .” Naunyn Schmiedeberg´s Arch Pharmacol, 2003 . 367, (Suppl 1): R22 .

Michael, S ., H . Abdel-Aziz, D . Weiser, C . E . Muller, O . Kelber and K . Nieber “Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®(R)) in rat small intestinal preparations .” Naunyn Schmiedebergs Arch Pharmacol, 2012 . 385(4): 411–421 .

Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis .” Mol Med, 2015 . 21(1): 1011–1024 .

Hasler WL, Gas and Bloating, Gastroenterol Hepatol (N Y). 2006 Sep; 2(9): 654–66

Burri, E ., E . Barba, J . W . Huaman, D . Cisternas, A . Accarino, A . Soldevilla, J . R . Malagelada, and F . Azpiroz "Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia ." Gut, 2014 . 63(3): 395-400 .

Csef, H . “Funktionelle (somatoforme) Störungen beim internistischen Hausbesuch .” Internist, 2001 . 42: 1476 .

Houghton, L . A ., M . Heitkemper, M . Crowell, A . Emmanuel, A . Halpert, J . A . McRoberts and B . Toner “Age, Gender and Women's Health and the Patient .” Gastroenterology, 2016 . 150(6): 1332–1343 .e1334 .

Metz, A . and G . Hebbard "Nausea and vomiting in adults--a diagnostic approach ." Aust Fam Physician, 2007 . 36(9): 688-92 .

Balaban, C . D . and B . J . Yates "What is nausea? A historical analysis of changing views ." Auton Neurosci, 2017 . 202: 5-17 .

Surdea-Blaga, T ., D . E . Negrutiu, M . Palage and D . L . Dumitrascu "Food and Gastroesophageal Reflux Disease ." Curr Med Chem, 2019 . 26(19): 3497-3511 .

Bustos, M ., R .  Venkataramanan and Steve Caritis "Nausea and vomiting of pregnancy - What's new? " Auton Neurosci, 2017. 202: 62-72 .

European Medicines Agency: EMA/HMPC/715092/2013 – “European Union herbal monograph on Carum carvi L ., fructus .” Published 14 November 2014 . Available from: https://www.ema.europa.eu/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-lfructus_en.pdf .

Carvi fructus, ESCOP monographs 2003.

Manuyakorn, W . and P . Tanpowpong "Cow milk protein allergy and other common food allergies and intolerances ." Paediatr Int Child Health, 2019 . 39(1): 32-40 .

Sierra, D ., M . Wood, S . Kolli and L . M . Felipez "Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease ." Pediatr Rev, 2018 . 39(11): 542-549 .

Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005 . 20(3): 332-9 .

Hachem, C . and N . J . Shaheen "Diagnosis and Management of Functional Heartburn ." Am J Gastroenterol, 2016 . 111(1): 53-61 .

Michaudet, C . and J . Malaty "Chronic Cough: Evaluation and Management ." Am Fam Physician, 2017 . 96(9): 575-580 .

Ghisa, M ., M . D . Coletta, I . Barbuscio, E . Marabotto, B . Barberio, M . Frazzoni, N . De Bortoli, P . Zentilin, S . Tolone, A . Ottonello, G . Lorenzon, V . Savarino and E . Savarino "Updates in the field of non-esophageal gastroesophageal reflux disorder ." Expert Rev Gastroenterol Hepatol, 2019 . 13(9): 827-838 .

Ness-Jensen, E ., K . Hveem, H . El-Serag and J . Lagergren "Lifestyle Intervention in Gastroesophageal Reflux Disease ." Clin Gastroenterol Hepatol, 2016 . 14(2): 175-82.e1-3 .

Thélin, C . S . and J . E . Richter "Review article: the management of heartburn during pregnancy and lactation ." Aliment Pharmacol Ther, 2020 . 51(4): 421-434 .

Yu, H . X ., C . S . Han, J . R . Xue, Z . F . Han and H . Xin "Esophageal hiatal hernia: risk, diagnosis and management ." Expert Rev Gastroenterol Hepatol, 2018 . 12(4): 319-329 .

Patti, M . G ., H . I . Goldberg, M . Arcerito, L . Bortolasi, J . Tong and L . W . Way "Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury ." Am J Surg, 1996 . 171(1): 182-6 .

Gabrielli, A . , E . V . Avvedimento and T . Krieg "Scleroderma ." N Engl J Med, 2009 . 360(19): 1989-2003 .

Adarsh, M . B ., S . K . Sharma, K . K . Prasad, V . Dhir, S . Singh and S . K . Sinha " Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis ." JGH Open, 2019 . 3(3): 206-209 .

Richter, J . E . "Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications ." Am J Gastroenterol, 2000 . 95(2): 368-73 .

Tullmann, D . F . and K . Dracup "Knowledge of heart attack symptoms in older men and women at risk for acute myocardial infarction ." J Cardiopulm Rehabil, 2005 . 25(1): 33-9 .

Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .

Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .

Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .

Koduru, P ., M . Irani and E . M . M . Quigley "Definition, Pathogenesis, and Management of That Cursed Dyspepsia ." Clin Gastroenterol Hepatol, 2018 . 16(4): 467-479 .

Ford, A . C ., A . Marwaha, R . Sood and P . Moayeddi "Global prevalence of, and risk factors for, univestigated dyspepsia: a meta-analysis ." Gut, 2015 . 64(7): 1049-57 .

Feinle-Bisset C . and F . Azpiroz "Dietary and lifestyle factors in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 150-7 .

Schiller, L . R . "Maldigestion Versus Malabsorption in the Elderly ." Curr Gastroenterol Rep, 2020 . 22(7): 33 .

Lindkvist, B . "Diagnosis and treatment of pancreatic exocrine insufficiency ." World J Gastroenterol, 2013 . 19(42): 7258-66 .

Deng, Y ., B . Misselwitz, N . Dai and M . Fox "Lactose Intolerance in Adults: Biological Mechanism and Dietary Management ." Nutrients, 2015 . 7(9): 8020-35 .

Wong, Y ., D . M . H . Freeland, K . C . Nadeau "Food allergy: immune mechanisms, diagnosis and immunotherapy ." Nat Rev Immunol, 2016 . 16(12): 751-765 .

Lebwohl, B ., D . S . Sanders and P . H . R . Green "Coeliac disease ." Lancet, 2018 . 391(10115): 70-81 .

Jones, H . F ., R . N . Butler and D . A . Brooks "Intestinal dructose transport and malabsorption in humans ." Am J Physiol Gastrointest Liver Physiol, 2010 . 300: G202-G206 .

Bredenoord, A . J . and A . J . P . Smout "Physiologic and pathologic belching ." Clin Gastroenterol Hepatol, 2007 . 5(7): 772-5 .

Angelicae radix, ESCOP monographs 2009.

Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006 . 13 (Suppl 5): 67–74 .

Gut & Brain References:

Furness, J . B . "The enteric nervous system and neurogastroenterology" Nat Rev Gastroenterol Hepatol, 2012 . 9: 286-294 .

Schneider, S ., C . M . Wright and R . O . Heuckeroth "Unexpected Roles for the Second Brain: Enteric Nverous System as Master Regulator of Bowel Function ." Annual Review of Physiology, 2019 . 81: 235-59 .

Dinan, T . G . and J . D . Cryan "The Microbiome-Gut-Brain Axis in Health and Disease ." Gastroenterol Clin N Am, 2017 . 46: 77-89 .

Galland, L . "The Gut Microbiome and the Brain ." Journal of Medicinal Food, 2017 . 12: 1261-1272 .

Ducarmon, Q . R ., R . D . Zwittink, B . V . H . Hornung, W . van Schaik, V . B . Young and E . J . Kuijper "Gut Micorbiota and Colonization Resistance against Bacterial Enteric Infection ." Microbiol Mol Biol Rev, 2019 . 83 (3): e00007-19 .

Rinninella, E ., P . Raoul, M . Cintoni, F . Franceschi, G . A . D . Miggiano, A . Gasbarrini and M . C . Mele "What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet and Diseases ." Microorganisms, 2019 . 7, 14 .

Lozupone, C . A ., J . I. Stombaugh, J . I . Gordon, J . K . Jansson and R . Knight "Diversity, stability and resilience of the human gut microbiota ." Nature, 2012 . 489 (7415): 220-230 .

Lynch, S . V . and O . Pederson "The Human Intestinal Microbiome in Health and Disease ." N Engl J Med, 2016 . 375(24):2369-2379 .

Kapitan, M ., M . J . Niemiec, A . Steimle, J . S . Frick and I . D . Jacobsen " Fungi as Part of the Microbiota and Interactions with Intestinal Bacteria ." Curr Top Microbiol Immunol, 2019 . 422: 265-301 .

Strandwitz, P . "Neurotransmitter modulation by the gut microbiota ." Brain Res, 2018 . 1693 (Pt B): 128-133 .

Baj, A ., E . Moro, M . Bistoletti, V . Orlandi, F . Crema and C . Giaroni "Glutamergic Signaling Along The Microbiota-Gut-Brain Axis ." Int J Mol Sci, 2019 . 20(6): 1482 .

Jenkins, T . A ., J . C . D . Nguyen, K . E . Polglaze and P . B . Bertrand "Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis." Nutrients, 2016 . 8(1): 56 .

Smith, R . P., C. Easson, S . M . Lyle. , R . Kapoor, C . P . Donnelly, E . J . Davidson, E . Parikh, J . V . Lopez and J . L . Tartar "Gut microbiome diversity is associated with sleep physiology in humans ." PLOS ONE, 2019 . 14(10): e0222394 .

Thaiss, C . A ., N . Zmora, M . Levy and E . Elinav "The microbiome and innate immunity" Nature, 2016. 535, 65-74 .

Rooks, M . G . and W . S . Garrett "Gut microbiota, metabolites and host immunity ." Nat Rev Immunol, 2016 . 16(6): 341-352 .

McDermott, A . J . and G . B . Huffnagle "The microbiome and regulation of mucosal immunity ." Immunology, 2014 . 142(1): 24-31 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005 . 20(3): 332-9 .

Berthoud, H . R . and W . L . Neuhuber "Functional and chemical anatomy of the afferenet vagal system ." Auton Neruosci, 2000 . 85(1-3): 1-17 .

Bonaz, B ., T . Bazin and S . Pellissier "The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis" Front Neurosci, 2018 . 12:49 .

Knowledge Overview References:

Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016 . 96: 2275-283 .

Furness, J . B . "The enteric nervous system and neurogastroenterology" Nat Rev Gastroenterol Hepatol, 2012 . 9: 286-294 .

Schneider, S ., C . M . Wright and R . O . Heuckeroth "Unexpected Roles for the Second Brain: Enteric Nverous System as Master Regulator of Bowel Function ." Annual Review of Physiology, 2019 . 81: 235-59 .

Lynch, S . V . and O . Pederson "The Human Intestinal Microbiome in Health and Disease ." N Engl J Med, 2016 . 375(24):2369-2379 .

Boeckxstaens, G ., M . Camilleri, D . Sifrim, L . A . Houghton, S . Elsenbruch, G . Lindberg, F . Azpiroz and H . P . Parkman "Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation ." Gastroenterology, 2016 . 150: 1292-1304 .

Filipović, B . F ., T . Randjelovic, N . Kovacevic, N . Milinić, O . Markovic, M . Gajić, B . R . Filipović "Laboratory parameters and nutritional status in patients with functional dyspepsia ." Eur J Intern Med, 2011 . 22(3): 300-4 .

Mullan, A ., P . Kavanagh, P . O'Mahony, T . Joy, F . Gleeson and M . J . Gibney "Food and nutrient intakes and eating patterns in functional and organic dyspepsia ." Eur J Clin Nutr, 1994 . 48(2): 97-105 .

Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients ." Dig Dis Sci, 2010 . 55(1): 60-5 .

Göktaş, Z ., S . Köklü, D . Dikmen, Ö . Öztürk, B . Yılmaz, M . Asıl, H . Korkmaz, Y . Tuna, M . Kekilli, E . K . Aksoy, H . Köklü, A . Demir, G . Köklü and S . Arslan " Nutritional habits in functional dyspepsia and its subgroups: a comparative study ." Scand J Gastroenterol, 2016 . 51(8): 903-7 .

Wallace, J . L . "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiol Rev, 2008 . 88(4): 1547-65 .

Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005 . 20(3): 332-9 .

Mayer, E . A ., S . Bradesi, L . Chang, B . M . R . Spiegel. J . A . Bueller and B . D . Naliboff "Functional GI disorders: from animal models to drug development ." Gut, 2008 . 57(3): 384-404 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

Von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Knowledge Articles References

Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016 . 96: 2275-283 .

Hosseinpour, M . and A . Behdad "Evaluation of small bowel measurement in alive patients ." Surgical and Radiologic Anatomy, 2008 . 30, 653-655 .

Bonaz, B ., T . Bazin and S . Pellissier "The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis" Front Neurosci, 2018 . 12:49 .

Berthoud, H . R . and W . L . Neuhuber "Functional and chemical anatomy of the afferenet vagal system ." Auton Neruosci, 2000 . 85(1-3): 1-17 .

Leung, P . S . "Overview of the Pancreas ." In: The Renin-Angiotensin System: Current Research Progress Progress in The Pancreas. Advances in Experimental Medicine and Biology, 2018 . Volume 690, Springer, Dordrecht, pp 3-12 .

Löhr, J . M ., N . Panic, M . Vujasinovic and C . S . Verbeke "The ageing pancreas: a systematic review of the evidence and analysis of the consequences ." J Intern Med, 2018 . 283(5) : 446- 460 .

Furness, J . B . "The enteric nervous system and neurogastroenterology" Nat Rev Gastroenterol Hepatol, 2012 . 9: 286-294 .

Schneider, S ., C . M . Wright and R . O . Heuckeroth "Unexpected Roles for the Second Brain: Enteric Nverous System as Master Regulator of Bowel Function ." Annual Review of Physiology, 2019 . 81: 235-59 .

Ford, A . C ., A . Marwaha, R . Sood and P . Moayeddi "Global prevalence of, and risk factors for, univestigated dyspepsia: a meta-analysis ." Gut, 2015 . 64(7): 1049-57 .

Enck, P ., F . Azpiroz, G . Boeckxstaens, S . Elsenbruch, C . Feinle-Bisset, G . Holtmann, J . M . Lackner, J . Ronkainen, M . Schemann, A . Stengel, J . Tack, S . Zipfel and N . J . Talley “Functional dyspepsia .” Nat Rev Dis Primers, 2017 . 3: 17081 .

Enck, P ., Q . Aziz, G . Barbara, A . D . Farmer, S . Fukudo, E . A . Mayer, B . Niesler, E . M . Quigley, M . Rajilic-Stojanovic, M . Schemann, J . Schwille-Kiuntke, M . Simren, S . Zipfel and R . C . Spiller “Irritable bowel syndrome .” Nat Rev Dis Primers, 2016 . 2: 16014 .

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

Von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086

Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .

Stanghellini, V ., F . K . Chan, W . L . Hasler, J . R . Malagelada, H . Suzuki, J . Tack and N . J . Talley “Gastroduodenal Disorders .” Gastroenterology, 2016 . 150(6): 1380–1392 .

Rasmussen, S ., T . H . Jensen, S . L . Henriksen, P . F . Haastrup, P . V . Larsen, J . Sondergaard and D . E . Jarbol “Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population .” Scand J Gastroenterol, 2015 . 50(2): 162–169 .

Karling, P ., K . F . Norrback, R . Adolfsson and A . Danielsson " Gastrointestinal symptoms are associated with hypothalamic-pituitary-adrenal axis suppression in healthy individuals ." Scand J Gastroenterol, 2007 . 42 (11): 1294-301 .

Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005 . 20(3): 332-9 .

Tack, J ., H . Piessevaux, B . Coulie, P . Caenepeel and J . Janssens “Role of impaired gastric accommodation to a meal in functional dyspepsia .” Gastroenterology, 1998 . 115(6): 1346–1352 .

Iovino, P ., C . Bucci, F . Tremolaterra, A . Santonicola and G . Chiarioni “Bloating and functional gastro-intestinal disorders: where are we and where are we going?” World J Gastroenterol, 2014 . 20(39): 14407–14419 .

Hayes, P . A ., M . H . Fraher and E . M . M . Quigley "Irritable bowel syndrome: the role of food in pathogenesis and management ." Gastroenterol Hepatol (N Y), 2014 . 10(3): 164-74 .

De Giorgio, R ., U . Volta and P . R . Gibson "Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?" Gut, 2016 . 65(1): 169-78 .

Catassi, G ., E . Lionetti, S . Gatti and C . Catassi "The Low FODMAP Diet: Many Question Marks for a Catchy Acronym ." Nutrients, 2017 . 9(3): 292 .

Camilleri, M ., B . Coulie and J . F . Tack “Visceral hypersensitivity: facts, speculations, and challenges .” Gut, 2001 . 48(1): 125–131 .

Drossman, D . A . and W . L . Hasler “Rome IV-Functional GI Disorders: Disorders of GutBrain Interaction .” Gastroenterology, 2016 . 150(6): 1257–1261 .

Holtmann, G ., A . Shah and M . Morrison “Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview .” Dig Dis, 2017 . 35 (Suppl 1): 5–13 .

Dinan, T . G . and J . D . Cryan "The Microbiome-Gut-Brain Axis in Health and Disease ." Gastroenterol Clin N Am, 2017 . 46: 77-89 .

Mayer, E . A ., S . Bradesi, L . Chang, B . M . R . Spiegel. J . A . Bueller and B . D . Naliboff "Functional GI disorders: from animal models to drug development ." Gut, 2008 . 57(3): 384-404 .

Filipović, B . F ., T . Randjelovic, N . Kovacevic, N . Milinić, O . Markovic, M . Gajić, B . R . Filipović "Laboratory parameters and nutritional status in patients with functional dyspepsia ." Eur J Intern Med, 2011 . 22(3): 300-4 .

Mullan, A ., P . Kavanagh, P . O'Mahony, T . Joy, F . Gleeson and M . J . Gibney "Food and nutrient intakes and eating patterns in functional and organic dyspepsia ." Eur J Clin Nutr, 1994 . 48(2): 97-105 .

Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients ." Dig Dis Sci, 2010 . 55(1): 60-5 .

Göktaş, Z ., S . Köklü, D . Dikmen, Ö . Öztürk, B . Yılmaz, M . Asıl, H . Korkmaz, Y . Tuna, M . Kekilli, E . K . Aksoy, H . Köklü, A . Demir, G . Köklü and S . Arslan " Nutritional habits in functional dyspepsia and its subgroups: a comparative study ." Scand J Gastroenterol, 2016 . 51(8): 903-7 .

Simmen, U ., O . Kelber, R . Jaeggi, B . Büter, S . N . Okpanyi and D . Weiser . “Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor .” Naunyn Schmiedeberg´s Arch Pharmacol, 2003 . 367, (Suppl 1): R22 .

Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55 .

Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .

Müller, M . H ., C . Y . Liu, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine .” Phytomedicine, 2006 . 13 (Suppl 5): 100–106 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Phillips, M ., A . Patel, P . Meredith, O . Will and C . Brassett " Segmental colonic length and mobility .", Ann R Coll Engl, 2015 . 97(6): 439-44 .

Lynch, S . V . and O . Pederson "The Human Intestinal Microbiome in Health and Disease ." N Engl J Med, 2016 . 375(24):2369-2379 .

Kapitan, M ., M . J . Niemiec, A . Steimle, J . S . Frick and I . D . Jacobsen " Fungi as Part of the Microbiota and Interactions with Intestinal Bacteria ." Curr Top Microbiol Immunol, 2019 . 422: 265-301 .

Lozupone, C . A ., J . I. Stombaugh, J . I . Gordon, J . K . Jansson and R . Knight "Diversity, stability and resilience of the human gut microbiota ." Nature, 2012 . 489 (7415): 220-230 .

Rinninella, E ., P . Raoul, M . Cintoni, F . Franceschi, G . A . D . Miggiano, A . Gasbarrini and M . C . Mele "What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet and Diseases ." Microorganisms, 2019 . 7, 14 .

Thaiss, C . A ., N . Zmora, M . Levy and E . Elinav "The microbiome and innate immunity" Nature, 2016. 535, 65-74 .

Rooks, M . G . and W . S . Garrett "Gut microbiota, metabolites and host immunity ." Nat Rev Immunol, 2016 . 16(6): 341-352 .

McDermott, A . J . and G . B . Huffnagle "The microbiome and regulation of mucosal immunity ." Immunology, 2014 . 142(1): 24-31 .

Giannelli, F . R . "Antibiotic-associated diarrhea ." JAAPA, 2017. 30(10): 46-47 .

Fond. G ., A . Loundou, N . Hamdani, W . Boukouaci, A . Dargel, J . Oliveira, M . Roger, R . Tamouza, M . Leboyer and L . Boyer "Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis ." Eur Arch Pyschiatry Clin Neurosci, 2014 . 264(8): 651-60 .

Ford, A . C ., P . Moayyedi, B . E . Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel, E . M . M . Quigley "American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation ." Am J Gastroenterol. 2014 . 109 Suppl 1: s2-26; quiz S27 .

Mayer, E . A ., S . Bradesi, L . Chang, B . M . R . Spiegel. J . A . Bueller and B . D . Naliboff "Functional GI disorders: from animal models to drug development ." Gut, 2008 . 57(3): 384-404 .

Hassanzadeh, S ., P . Saneei, A . H . Keshteli, H . Daghaghzadeh, A . Esmaillzadeh and P . Adibi "Meal frequency in relation to prevalence of functional dyspepsia among Iranian adults ." Nutrition, 2016 . 32(2): 242-8 .

Ford, A . C ., E . M . M . Quigley, B . E . Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel and P . Moayyedi "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis ." Am J Gastroenterol, 2014 . 109(10): 1546, 1562 .

Moayyedi, P ., E . M . M . Quigley, B . E. Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel and A . C . Ford "The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis ." Am J Gastroenterol, 2014 . 109(9): 1367-74 .

Feinle-Bisset C . and F . Azpiroz "Dietary and lifestyle factors in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 150-7 .

Halmos, E . P ., V . A . Power, S . J . Shepherd, P . R . Gibson and J . G . Muir "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome ." Gastroenterology, 2014 . 146(1): 67-75 e5 .

Halmos, E . P ., C . T . Christophersen, A . R . Bird, S . J . Shepherd, P . R . Gibson and J . G . Muir "Diets that differ in their FODMAP content alter the colonic luminal microenvironment ." Gut, 2015 . 64(1): 93-100 .

Pilichiewicz, A . N ., M . Horowitz, G . J . Holtmann, N . J . Talley and C . Feinle-Bisset "Relationship between symptoms and dietary patterns in patients with functional dyspepsia ." Clin Gastroenterol Hepatol, 2009 . 7(3): 317-22 .

Berg, L . K ., E . Fagerli, M . Martinussen, A . O . Myhre, J . Florholmen and R . Goll "Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test ." Scand J Gastroenterol, 2013 . 48(8): 936-43 .

Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis .” Mol Med, 2015 . 21(1): 1011–1024 .

Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .

Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .

Michael, S ., H . Abdel-Aziz, D . Weiser, C . E . Muller, O . Kelber and K . Nieber “Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®(R)) in rat small intestinal preparations .” Naunyn Schmiedebergs Arch Pharmacol, 2012 . 385(4): 411–421 .

Wadie, W ., H . Abdel-Aziz, H . F . Zaki, O . Kelber, D . Weiser and M . T . Khayyal “STW 5 is effective in dextran sulfate sodium-induced colitis in rats .” Int J Colorectal Dis, 2012 . 27(11): 1445–1453 .

Holscher, H . D . "Dietary fiber and prebiotics and the gastrointestinal microbiota ." Gut Microbes, 2017 . 8(2): 172-184 .

Markowiak P . and K . Śliżewska " Effects of Probiotics, Prebiotics, and Synbiotics on Human Health ." Nutrients, 2017 . 9(9): 1021 .

Guandalini, S . "Probiotics for prevention and treatment of diarrhea ." J Clin Gastroenterol, 2011 . 45 Suppl: S149-53 .

Yuan, F ., H . Ni, C . V . Asche, M . Kim, S . Walayat and J . Ren "Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis ." Curr Med Res Opin, 2017 . 33(7): 1191-1197 .

Bonfrate, L ., D . M . Di Palo, G . Celano, A . Albert, P . Vitellio, M . De Angelis, M . Gobbetti and P . Portincasa "Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients ." Eur J Clin Invest, 2020 . 50(3):e13201 .

Pinto-Sanchez, M . I ., G . B . Hall, K . Ghajar, A . Nardelli, C . Bolino, J . T . Lau, F . P . Martin, O . Cominetti, C . Welsh, A . Rieder, J . Traynor, C . Gregory, G . De Palma, M . Pigrau, A . C . Ford, J . Macri, B . Berger, G . Bergonzelli, M . G . Surette, S . M . Collins, P . Moayyedi and P . Bercik "Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome ." Gastroenterology, 2017 . 153(2): 448-459.e8 .

Clifton, P . M . and J . B . Keogh "  A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease ." Nutr Metab Cardiovasc Dis, 2017 . 27(12): 1060-1080 .

Surdea-Blaga, T ., D . E . Negrutiu, M . Palage and D . L . Dumitrascu "Food and Gastroesophageal Reflux Disease ." Curr Med Chem, 2019 . 26(19): 3497-3511 .

Schubert, M . L . and D . A . Peura "Control of gastric acid secretion in health and disease ." Gastroenterology, 2008 . 134(7): 1842-60 .

Reichling, J . and R . Saller “Iberis amara L . (Bittere Schleifenblume) – Profil einer Heilpflanze .” Forsch Komplementärmed Klass Naturheilkd, 2002 . 9: 21–33 .

Iberis, Hager ROM 2003, Springer Verlag, Heidelberg 2003, HN: 2001400.

European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https://www.ema.europa.eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en.pdf .

Matricariae flos, ESCOP monographs 2003.

Flos Chamomillae, WHO monograph 2010.

Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .

Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .

Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .

Fujiwara, Y ., M . Kubo, Y . Kohata, H . Machida, H . Okazaki, H . Yamagami, T . Tanigawa, K . Watanabe, T . Watanabe, K . Tominaga and T . Arakawa "Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome ." Intern Med. 2011 . 50(21): 2443-7 .

Wallace, J . L . "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiol Rev, 2008 . 88(4): 1547-65 .

Sipponen, P . and H . I . Maaroos "Chronic gastritis ." Scand J Gastroenterol, 2015 . 50(6): 657-67 .

Ricci, C ., J . Holton and D . Vaira "Diagnosis of Helicobacter pylori: invasive and non-invasive tests ." Best Pract Res Clin Gastroenterol, 2007 . 21(2): 299-313 .

Annibale. B ., G . Esposito and E . Lahner " A current clinical overview of atrophic gastritis ." Expert Rev Gastroenterol Hepatol, 2020 . 14(2): 93-102 .

Wallace, J . L . "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiol Rev, 2008 . 88(4): 1547-65 .

Coffey, R . J ., M . K . Washington, C . L . Corless and M . C . Heinrich "Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach ." J Clin Invest, 2007 . 117(1): 70-80 .

Galland, L . "The Gut Microbiome and the Brain ." Journal of Medicinal Food, 2017 . 12: 1261-1272 .

Ducarmon, Q . R ., R . D . Zwittink, B . V . H . Hornung, W . van Schaik, V . B . Young and E . J . Kuijper "Gut Micorbiota and Colonization Resistance against Bacterial Enteric Infection ." Microbiol Mol Biol Rev, 2019 . 83 (3): e00007-19 .

Lozupone, C . A ., J . I. Stombaugh, J . I . Gordon, J . K . Jansson and R . Knight "Diversity, stability and resilience of the human gut microbiota ." Nature, 2012 . 489 (7415): 220-230 .

Rinninella, E ., P . Raoul, M . Cintoni, F . Franceschi, G . A . D . Miggiano, A . Gasbarrini and M . C . Mele "What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet and Diseases ." Microorganisms, 2019 . 7, 14 .

Strandwitz, P . "Neurotransmitter modulation by the gut microbiota ." Brain Res, 2018 . 1693 (Pt B): 128-133 .

Baj, A ., E . Moro, M . Bistoletti, V . Orlandi, F . Crema and C . Giaroni "Glutamergic Signaling Along The Microbiota-Gut-Brain Axis ." Int J Mol Sci, 2019 . 20(6): 1482 .

Jenkins, T . A ., J . C . D . Nguyen, K . E . Polglaze and P . B . Bertrand "Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis." Nutrients, 2016 . 8(1): 56 .

Smith, R . P., C. Easson, S . M . Lyle. , R . Kapoor, C . P . Donnelly, E . J . Davidson, E . Parikh, J . V . Lopez and J . L . Tartar "Gut microbiome diversity is associated with sleep physiology in humans ." PLOS ONE, 2019 . 14(10): e0222394 .

Berthoud, H . R . and W . L . Neuhuber "Functional and chemical anatomy of the afferenet vagal system ." Auton Neruosci, 2000 . 85(1-3): 1-17 .

Bonaz, B ., T . Bazin and S . Pellissier "The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis" Front Neurosci, 2018 . 12:49 .

Power of Nature References:

Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .

Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .

Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .

Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .

Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .

Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .

Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .

Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .

Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .

von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .

Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .

Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .

Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .

Reichling, J . and R . Saller “Iberis amara L . (Bittere Schleifenblume) – Profil einer Heilpflanze .” Forsch Komplementärmed Klass Naturheilkd, 2002 . 9: 21–33 .

Iberis, Hager ROM 2003, Springer Verlag, Heidelberg 2003, HN: 2001400.

Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .

Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .

Germann, I ., D . Hagelauer, O . Kelber, B . Vinson, S . Laufer, D . Weiser, H . Heinle "Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®)." Phytomedicine, 2006 . 13: p. 45-50.

Schempp, H ., A . Toth, D . Weiser, E . F . Elstner "Antioxidative properties of Iberis amara extracts in biochemical model reactions ." Arzneimittelforschung, 2003 . 13677247

Schempp, H ., S . Hippeli, D . Weiser, O . Kelber, E . F . Elstner "Comparison of the inhibition of myeloperoxidase-catalyzed hypochlorite formation in vitro and in whole blood by different plant extracts contained in a phytopharmacon treating functional dyspepsia ." Arzneimittelforschung, 2004 . 54(7):389-95 .

Wald, K ., O . Kelber, D . Weiser, S . Laufer, H . Heinle "Antioxidant properties of STW 5 and its single extracts on histamine-induced radical production of murine ileum ." Z Phytother, 2009 . 30(Suppl. 1): p. S36.

Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.

Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .

Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .

Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .

Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .

Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55.

Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006 . 13 (Suppl 5): 67–74 .

Angelicae radix, ESCOP monographs 2009.

European Medicines Agency: EMA/HMPC/614586/2012 – “Assessment report on Angelica sinensis (Oliv .) Diels, radix .” Published 9 July 2013 . Available from: https://www.ema.europa.eu/documents/herbal-report/final-assessment-report-angelica-sinensis-oliv-diels-radix-first-version_en.pdf .

European Medicines Agency: EMA/HMPC/715092/2013 – “European Union herbal monograph on Carum carvi L ., fructus .” Published 14 November 2014 . Available from: https://www.ema.europa.eu/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-lfructus_en.pdf .

Carvi fructus, ESCOP monographs 2003.

European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https:// www.ema.europa.eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en.pdf .

Matricariae flos, ESCOP monographs 2003.

Flos Chamomillae, WHO monograph 2010.

European Medicines Agency: EMA/HMPC/294188/2013 – “Assessment report on Silybum marianum (L .) Gaertn ., fructus .” Published 5 June 2018 . Available from: https://www.ema.europa.eu/documents/herbal-report/final-assessment-report-silybum-marianum-l-gaertn-fructus_en.pdf.

Fructus Silybi Mariae, WHO monograph 2002.

Silybi mariani fructus, ESCOP monographs 2009.

European Medicines Agency: EMA/HMPC/196746/2012 – “Assessment report on Melissa officinalis L ., folium .” Published 14 May 2013 . Available from: https://www.ema.europa.eu/documents/herbal-report/final-assessment-report-melissa-officinalis-l-folium_en.pdf .

Melissae folium, ESCOP monographs 2013.

Folium Melissae, WHO monograph 2010.

Bonaterra, G ., R . Kinscherf, O . Kelber, D . Weiser and J . Metz “Antiinflammatorische und antiproliferative Wirkung von Iberogast® in vitro .” Z Gastroenterol, 2008 . 46(09): P352 .

Bonaterra, G . A ., O . Kelber, D . Weiser and R . Kinscherf “Mechanisms of the antiproliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro .” Phytomedicine, 2013 . 20(8–9): 691–698 .

Voß, U ., F . Herr, N . Störmer, S . Okpanyi, D . Weiser, O . Kelber, H . Abdel-Aziz and K . Nieber, “Effects of STW 5, STW 5II and their components on contractility of inflamed rat colon preparations .” Young Researchers Meeting . Münster, 2012 .

Sibaev, A ., H . Abdel-Aziz, O . Kelber, H . D . Allescher and M . Storr “Mechanism of action of STW 5 and its components on motility and intestinal neurotransmission in “in vitro” model of the human colon .” Neurogastroenterol Motil, 2015 . 27 (Suppl . 2): 101 .

European Medicines Agency: EMA/HMPC/369801/2009 – “Assessment report on Chelidonium majus L ., herba .” Published 13 September 2011 . Available from: https://www.ema.europa.eu/documents/herbal-report/final-assessment-report-chelidonium-majus-l-herba_en.pdf .

Herba Chelidonii, WHO monograph 2010.

Holtmann, G ., D . Schrenk, A . Madisch, H . D . Allescher, G . Ulrich-Merzenich, F . Mearin, D . Larrey and P . Malfertheiner "Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Dirsorders: A conceptional Framework for Risk-Benefit Assessment and Regulatory approaches " Dig Dis, 2019 . online, DOI: 10.1159/000504570

European Medicines Agency: EMEA/HMPC/193910/2007 – “Assessment report on Mentha X piperita L ., folium .” Published 4 September 2008 . Available from: https://www.ema.europa.eu/documents/herbal-report/assessment-report-mentha-x-piperita-l-folium_en.pdf .

Menthae piperitae folium, ESCOP monographs 2019.

Folium Menthae Piperitae, WHO monograph 2002.

Allam, S ., D . Krueger, I . E . Demir, G . Ceyhan, F . Zeller and M . Schemann “Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine .” Phytomedicine, 2015 . 22(12): 1063–1070 .

European Medicines Agency: EMA/HMPC/571122/2010 Corr . – “Assessment report on Glycyrrhiza glabra L . and/or Glycyrrhiza inflata Bat . and/or Glycyrrhiza uralensis Fisch ., radix .” Published 12 March 2013 . Available from: https://www.ema.europa.eu/documents/herbal-report/final-assessmentreport-glycyrrhiza-glabra-l/glycyrrhiza-inflata-bat/glycyrrhiza-uralensis-fisch-radix_en.pdf .

Liquiritiae radix, ESCOP monographs 2003.

Radix Glycyrrhizae, WHO monograph 2010.

Product Reference:

Professional Information Leaflet

Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625.

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .

FAQ References:

Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19.

Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72.